Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against GSK plc(GSK)
06:01pm, Saturday, 01'st Mar 2025
NEW YORK, NY / ACCESS Newswire / March 1, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the
ROSEN, A LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
12:00pm, Saturday, 01'st Mar 2025
NEW YORK, NY / ACCESS Newswire / March 1, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between Febru
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against GSK plc
11:00am, Saturday, 01'st Mar 2025
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Compa
NEW YORK, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to c
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow
NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between Febru
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow
Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK
11:30am, Friday, 28'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow
A Securities Fraud Lawsuit Has Been Filed Against GSK plc And Investors With Losses Are Urged To Contact The Schall Law Firm
11:00am, Friday, 28'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc ("GSK" or "the C
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow
NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GS
NEW YORK , Feb. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit se
Shareholders of GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – GSK
10:40pm, Thursday, 27'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow
GSK plc Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – GSK
09:00pm, Thursday, 27'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK) Such investors are advised t
